Repetitive short‐course hepatic arterial infusion chemotherapy with high‐dose 5‐fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma

Abstract

BACKGROUND. Hepatic arterial infusion chemotherapy (HAIC) has often been selected as a therapeutic option for patients with advanced hepatocellular carcinoma (HCC). The objective of the current study was to evaluate the efficacy and safety of repetitive HAIC with high‐dose 5‐fluorouracil (5‐FU) and cisplatin given for 3 days in patients with advanced HCC. METHODS. Between January 2001 and December 2004, a total of 41 patients with unresectable advanced HCC were enrolled. The patients underwent HAIC via the implantable port system with 5‐FU (at a dose of 500 mg/m² on Days 1–3) and cisplatin (at a dose of 60 mg/m² on Day 2) every 4 weeks. Tumor response was assessed at the end of every 3 cycles. RESULTS. The median age of the patients was 53 years and 34 patients (82.9%) had evidence of portal vein thrombosis. In total, 230 cycles of HAIC were administered to the 41 patients, with a median of 6 cycles given (range, 1–14 cycles). Nine patients (22.0%) achieved a partial response and 14 patients (34.1%) had stable disease. The median time to disease progression and overall survival were 7.0 months and 12.0 months, respectively. The overall survival was found to be significantly longer in the successful disease control group (patients with a complete response, partial response, and stable disease) than in the disease progression group (median of 14.0 months vs 6.0 months; P < .001). Adverse reactions were tolerable and successfully managed with conservative treatment. CONCLUSIONS. HAIC with high‐dose 5‐FU and cisplatin given for 3 days achieved effective and safe results in patients with advanced HCC. Therefore, repetitive short‐course HAIC with high‐dose 5‐FU and cisplatin may be useful as an alternative therapeutic option for patients with advanced HCC. Cancer 2007. © 2007 American Cancer Society.